No Data
No Data
As Small-caps Ride the Trump Wave, Here Are the Best & Worst Such Stocks as per SA Quant
Poseida Therapeutics Insider Sold Shares Worth $283,866, According to a Recent SEC Filing
BTIG Maintains Poseida Therapeutics(PSTX.US) With Hold Rating
Cautious Hold Rating on Poseida Therapeutics Amid Promising Data and Strategic Uncertainties
Roche Launches Tender Offer for Poseida Therapeutics
Roche Commences Tender Offer for All Shares of Poseida Therapeutics, Inc. for $9.00 per Share in Cash, Plus a Non-tradeable Contingent Value Right for up to $4.00 per Share in Cash
No Data